Wikidata

(Q64139373)

English

A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas

clinical trial

In more languages

Statements

title
A Phase 1B Study Evaluating RO7082859 in Combination With Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) or in Participants With Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (English)
0 references
sponsor
Hoffmann-La Roche
0 references
country
Australia
0 references
Canada
0 references
Denmark
0 references
Germany
0 references
Italy
0 references
Spain
0 references
United Kingdom
0 references
start time
13 March 2018
0 references
end time
17 June 2023
0 references
number of participants
172
0 references
research intervention
(RS)-cyclophosphamide
0 references
rituximab
0 references
doxorubicin
0 references
Caelyx
0 references
prednisone
0 references
minimum age
18 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q64139373&oldid=1857558143"